listed IMPACT jumps as EC approves Senaparib for ovarian cancer treatment
** Shares of IMPACT Therapeutics Inc 7630.HK jump as much as 27.9% to HK$11.93, their highest level since October 22
** Stock last up 15.1%, on course for the biggest one-day pct gain since September 21 in the third straight session of gains
** China-based pharmaceutical products developer says European Commission has granted approval for its self-developed innovative drug Senaparib for maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer
** Company says it is advancing the clinical and regulatory development of senaparib globally, and it is pursuing life cycle management for Senaparib, exploring combination therapy opportunities, and expanding into multiple indications
** Since debut on May 13, stock down 46.6% from HK$20.10 apiece offer price
** YTD, Hang Seng Biotech Index .HSBIO up 0.8%